两种新的选择性环氧合酶-2抑制剂

被引:34
作者
陈望忠
机构
[1] 军事医学科学院毒物药物研究所!北京
关键词
环氧合酶-1; 环氧合酶-2; 美洛昔康; 氯诺昔康;
D O I
10.13220/j.cnki.jipr.1997.03.011
中图分类号
R979.5 [免疫增强剂、免疫抑制剂];
学科分类号
1007 ;
摘要
选择性环氧合酶 2 (COX 2 )抑制剂已成为寻找副作用小的、非甾体类抗炎药的研究方向。美洛昔康与氯诺昔康是两种结构不同的昔康类非甾体抗炎药 ,所具有的消炎镇痛作用及良好的胃肠道耐受性与它们对COX 2的选择性抑制作用有关。本文报道了美洛昔康和氯诺昔康对COX 2的选择性抑制作用及相应的药效学和药动学性质。
引用
收藏
页码:168 / 171
页数:4
相关论文
共 21 条
[1]  
A randomized, double-blind, placebo-controlled, dose-response study of the analgesic effect of lornoxicam after surgical removal of mandibular third molars. Norholt SE,Sindet-Pedersen S,Bugge C,et al. Journal of Clinical Pharmacology . 1995
[2]  
Intravenous administration of lornoxicam, a new NSAID, and pethidine for postoperative pain.A placebo-controlled pilot study. Rosenow DE,van Krieken F,Stolke D,et al. Clinical Drug Investigation . 1996
[3]  
Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Olkkola KT,Brunetto AV,Mattila MJ. Clinical Pharmacokinetics . 1994
[4]  
Pharmacologic management of cancer pain. Levy MH. Seminars in Oncology . 1994
[5]  
A longterm study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Huskisson EC,Ghozlan R,Kurthen R,et al. British Journal of Rheumatology . 1996
[6]  
An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Bevis PJR,Bird HA,Lapham G. British Journal of Rheumatology . 1996
[7]  
Safety of meloxicam: a global analysis of clinical trials. Distel M,Mueller C,Bluhmki E,et al. British Journal of Rheumatology . 1996
[8]  
Comparisonoftheonsetandintensityofactionofintramuscularmeloxicamandoralmeloxicaminpatientswithacutesci atica. AuvinetB,ZillerR,AppelboomT,etal. Clinical Therapeutics . 1995
[9]  
Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Hosie J,Distel M,Bluhmki E. British Journal of Rheumatology . 1996
[10]  
A six-month double-blind trial to compare the efficacy and safety of meloxicam 7. 5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Wojtulewski JA,Schattenkirchner M,Barcelo P,et al. British Journal of Rheumatology . 1996